Product Images Ocella

This text provides a list of relevant studies that have evaluated the risk of breast cancer associated with the use of combined oral contraceptives. The studies included in the list compare ever use versus never use of COCs, as well as current use versus never use. The text also includes some statistical information, including effect estimates such as odds ratios (OR), relative risks (RR), and hazard ratios (HR) for the association between COC use and breast cancer risk.*

This text seems to describe different ranges of blood clot occurrence in women based on various factors such as pregnancy, postpartum period, and use of contraception. It also provides a numerical representation of the blood clot rate per 10,000 Women Years (WY). However, the description is incomplete and lacks context.*

Drospirenone Ethinyl Estradiol is a combination of two hormones that are used in birth control pills. Ethinyl estradiol is a synthetic estrogen and drospirenone is a synthetic progestin. This medication works by preventing ovulation and thickening cervical mucus, making it harder for sperm to reach the uterus. It is also used to treat premenstrual dysphoric disorder and moderate acne in women. It is important to take this medication as directed by your healthcare provider to ensure maximum effectiveness and to reduce the risk of side effects.*

This text appears to be describing different methods of birth control and the effectiveness rates for each. It provides information on the number of pregnancies per 100 women with and without the use of various birth control methods, including injections, sterilization, birth control pills, condoms, and natural family planning methods such as withdrawal and tracking fertile days. It also mentions some methods by name, including diaphragms and intrauterine devices.*

The text contains some weekdays and a brand name "OCELLA™" followed by two drug names, "DROSPIRENONE & ETHINYL ESTRADIOL". There are some numbers and characters as well, but they are not readable. It seems like the text is a part of a schedule or a label, and the drug names are used for some medication.*

This text provides information on the rate of blood clot incidents in women who are not pregnant, non-COC users, COC users, pregnant or postpartum. The data consists of ranges and the number of women with a blood clot out of 10,000 women years (WY). It also includes a note about the pregnancy data being based on actual duration or nine months, with a rate of 7-27 per 10,000 WY.*